Study of Nivolumab With or Without Pazopanib in Metastatic or Unresectable Soft Tissue Sarcomas
Status:
Withdrawn
Trial end date:
2022-06-01
Target enrollment:
Participant gender:
Summary
This trial will assess whether nivolumab alone or nivolumab combined with pazopanib will be
associated with an improvement in progression free survival (PFS) at 6 months
Phase:
Phase 2
Details
Lead Sponsor:
New York University School of Medicine NYU Langone Health